Not known Facts About YX-2-107
The primary end issue was the protection and tolerability of sifalimumab. Cure-emergent adverse functions (AEs) and serious AEs (SAEs) as well as their severity, outcome, and any connection towards the examine medication were recorded from the investigator through the research. AEs ended up deemed likely to be related to research medication should